Poseida Entered into a Collaboration and License Agreement with Roche for Allogeneic CAR-T Cell Therapies to Treat Hematologic Malignancies
- Roche gets exclusive global rights for allogeneic CAR-T cell therapy products incl. P-BCMA-ALLO1 & P-CD19CD20-ALLO1 (Tier 1 program) & options for P-BCMACD19-ALLO1 & P-CD70-ALLO1 (Tier 2 program); exclusive license for allogeneic CAR-T cell therapy products from ~6 collaboration programs (designated by Roche) & option for a non-exclusive, commercial license for ~3 solid tumor targets (licensed products)
- If, Roche exercises its option for the Tier 2 program, Poseida will receive an option exercise fee. Before transferring the technology to Roche, Poseida will lead the manufacturing activities (Tier 1 & 2 programs)
- Poseida to receive $110M up front, ~ $110M in near-term milestones & is eligible to receive reimbursements, fees & milestones of ~$6.0B incl. ~$1.5B & $1.1B for Tier 1 & 2 programs; $2.9B & $415.0M for the collaboration programs & licensed products along with royalty from the Tier 1 & 2 programs, collaboration programs & for licensed products
Ref: PR Newswire | Image: Poseida Therapeutics
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.